• Jimini Health

  Participated · Seed · Apr 2026

  Jimini Health builds clinician-supervised AI infrastructure for behavioral health provider organizations, with a flagship platform called Sage that integrates into regulated clinical environments. Sage is designed so licensed clinicians maintain oversight of every patient interaction while enabling providers to deploy AI at scale. The company emphasizes compliance with regulatory requirements and direct integration with clinical workflows. Jimini plans to expand AI development across additional clinical settings and scale partnerships with large behavioral health providers nationwide using proceeds from its recent financing. Financially, the company raised a $17M Seed round led by M13, bringing total funding to over $25M. Jimini Health is based in New York and is led by CEO Luis Voloch.

• Ceretype Neuromedicine

  Participated · Seed · Jan 2024

  Ceretype Neuromedicine is a Cambridge, MA-based company that focuses on the practical application and integration of functional MRI (fMRI) in neuropsychiatric drug development and beyond. Led by CEO Emily Stern, the company’s platform makes targeted biomarkers accessible and delivers actionable evidence to improve drug discovery and patient care. Through its technical approach and its ability to sub-type and classify the human brain on a neurobiological level, Ceretype offers biologically-based therapeutic insights. The company closed its second round of seed financing with a $2M funding target that was oversubscribed. Ceretype intends to use the funds to help advance its fMRI platform. Investors in the round included Cedar Street Group as lead, along with Leafy Tunnel, The One Mind Accelerator and private investors.

• Heading Health

  Participated · Series A · Jun 2023

  Heading Health combines evidence-based mental health care with personalized treatment plans, offering a continuum of in-network services for hard-to-treat conditions. The company provides interventional psychiatric services in its centers, including intramuscular ketamine, Spravato, and TMS, alongside psychiatry and therapy via telehealth. Founded in 2020 by co-founders Steve Levine, MD, and CEO Simon Tankel, Heading operates locations in the Austin and Dallas–Fort Worth metros. It plans further expansion in Dallas and a first location in Houston later this year. Heading intends to use new funding to scale into new markets and to invest in its care delivery and analytics platform. The company recently completed a notable financing round, signaling early-stage investor interest in its in-network, intervention-capable care model.

• MiResource

  Participated · Seed · Aug 2021

  MiResource operates an automated, online referral marketplace that guides patients and care providers to identify the right mental health care for individual needs. The platform creates hyperlocal micro-marketplaces via partnerships with university counseling centers and focuses primarily on university students. The company has established contracts with 25 university health systems and has helped connect over 50,000 students to a network of more than 5,000 mental health providers. Led by CEO Mackenzie Drazan and COO Gabriela Asturias, MiResource removes the knowledge burden from patients and providers to help them navigate the mental health care system. The company plans to use the new funding to continue expanding its automated referral platform. The article states the company is based in San Mateo, CA.

• Mindstrong Health

  Participated · Series A · Jun 2017

  Mindstrong Health operates a digital care platform that uses smartphone-derived digital biomarkers and teletherapy to monitor and treat people with severe mental illnesses such as schizophrenia, bipolar disorder, obsessive-compulsive disorder and major depressive disorder. The company passively measures phone usage and keyboard-timing metrics to assess mental acuity and emotional valence; those measures are currently being validated in clinical trials. It provides access to therapists via phone, video and asynchronous text and positions its offering as a virtual hospital with complex care pathways for this population. Founder Paul Dagum has worked on these monitoring approaches since 2013 and remains the company’s chief scientific officer. Daniel Graf, an ex‑Uber executive, joined as CEO in November as Mindstrong moves from pure R&D toward commercial availability. The company frames the market need as large and costly to the U.S. healthcare system (roughly $20 billion per month) and says its platform could have broader applications across healthcare. Mindstrong Health develops measurement-science solutions and integrated health services designed to detect mental illness early and deliver preemptive care to improve outcomes. The company markets a diagnostic approach and care-delivery model aimed at modernizing mental health treatment. Mindstrong is led by Founder and CEO Paul Dagum and is based in Palo Alto, California. It is backed by a group of investors that includes ARCH Venture Partners, Foresite Capital, Bezos Expeditions, Decheng Capital, Berggruen Holdings, and One Mind Brain Health Impact Fund. Recently the company expanded its Series B financing with an additional $31 million investment. Board changes accompanying the financing include General Catalyst’s Hemant Taneja joining the board and Stephen K. Klasko joining as an independent director. Mindstrong Health develops measurement science that passively and continuously measures brain function through individuals' interactions with smartphones to detect cognitive and mood deterioration early. Its offerings include a patient-facing app, a provider-facing product, and clinical services delivered via a telehealth-enabled engagement and measurement platform. The company says its digital measures predict performance on gold-standard neurocognitive tests and is advancing clinical and translational research across brain health conditions globally. Mindstrong has partnered with pharmaceutical and clinical organizations, including Takeda Pharmaceutical Company Limited and Blackthorn Therapeutics, to apply its technology to identify digital biomarkers in conditions such as schizophrenia and treatment-resistant depression. The company announced a $15 million Series B and will use proceeds to scale the business and advance commercial deployments with partners across healthcare verticals. To date Mindstrong has raised $29 million following a $14 million Series A in June 2017. Mindstrong Health has developed patented science that transforms patterns of interaction on a smartphone into continuous, objective digital biomarkers of mood and cognition. The platform measures processing speed, attention, memory and executive function based on four years of clinical research. Mindstrong's products are in clinical trials with payers, providers, academics and the pharmaceutical industry. The company says its approach delivers real-time, high-resolution measures of brain function that could modernize assessment and intervention in behavioral health. Mindstrong was established in 2014 and is based in Palo Alto, California. In June 2017 it announced a $14 million Series A to support its technology and clinical operations expansion.

No current team members are available.